Fig. 7From: Pembrolizumab in combination with gemcitabine for patients with HER2-negative advanced breast cancer: GEICAM/2015–04 (PANGEA-Breast) studyBaseline median values of MDSCs in ABC patients and healthy cohortBack to article page